INFI). All you have to do is sign up today for this free limited time offer by clicking the link below. On January 16 th, …
GAINERS 1. Infinity Pharmaceuticals Inc. (INFI) Gained 123.35% to close Thursday's (Oct.12) trading at $3.73. News: The Company will be reporting clinical and translational data from monotherapy dose-escalation component of its ongoing …
Register for free on Stock-Callers.com and download the latest research report on INFI at: http://stock …
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium …
It has been about a month since the last earnings report for Infinity Pharmaceuticals, Inc. INFI. Shares have lost about 5.3% in the past month, underperforming the market. Will the recent negative trend continue leading up to the stock's …
It may not reach its all-time highs any time soon, but even getting half its zenith would be a major boon for VRX stock. Another name among hard-hit pharma stocks is Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Already flirting with …
Infinity is an ideal candidate for a short sale. Infinity Pharmaceuticals (NASDAQ:INFI) has a short interest of 8%, which shows the generally positive mood on the Street for this stock. Despite the recent P2 failure of IPI-145 for RA, and its …
Investors are likely punishing INFI's stock price, knowing that each delay pushes ... This is one of a few articles in a series by David Phillips highlighting "Drugs that Disappointed Investors in 2013," and what we can learn from the ride.
It has been about a month since the last earnings report for Infinity Pharmaceuticals, Inc. INFI. Shares have lost about 5.3% in the past month, underperforming the market. Will the recent negative trend continue leading up to the stock's …